Form 4: PMV Pharmaceuticals Director Receives Stock Option Grant

Director Charles M. Baum was granted 42,000 stock options in PMV Pharmaceuticals, Inc. as part of a standard equity incentive.

Summary

• Director Charles M. Baum received a grant of 42,000 stock options on June 4, 2026.
• The options have an exercise price of $1.19 per share.
• The options are set to expire on June 4, 2036.
• Vesting occurs on the earlier of June 4, 2027, or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock.
• Potential for the options to remain underwater if the stock price does not exceed the $1.19 exercise price.

Future Outlook

The options vest in one year, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical non-employee director compensation packages for small-cap biopharmaceutical companies.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 4, 2027, or the next annual meeting.

Key Dates

Keywords

PMVP, PMV Pharmaceuticals, Form 4, Insider Trading, Stock Options, Director Compensation